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Abstract
This paper reviews current knowledge on the role of the
long-chain polyunsaturated fatty acids (LC-PUFA), doco-
sahexaenoic acid (DHA, C22:6n-3) and arachidonic acid
(AA, 20:4n-6), in maternal and term infant nutrition as well
as infant development. Consensus recommendations
and practice guidelines for health-care providers sup-
ported by the World Association of Perinatal Medicine,
the Early Nutrition Academy, and the Child Health Foun-
dation are provided. The fetus and neonate should
receive LC-PUFA in amounts sufficient to support opti-
mal visual and cognitive development. Moreover, the
consumption of oils rich in n-3 LC-PUFA during preg-
nancy reduces the risk for early premature birth. Pregnant
and lactating women should aim to achieve an average
daily intake of at least 200 mg DHA. For healthy term
infants, we recommend and fully endorse breastfeeding,
which supplies preformed LC-PUFA, as the preferred
method of feeding. When breastfeeding is not possible,
we recommend use of an infant formula providing DHA
at levels between 0.2 and 0.5 weight percent of total
fat, and with the minimum amount of AA equivalent to
the contents of DHA. Dietary LC-PUFA supply should
continue after the first six months of life, but currently
there is not sufficient information for quantitative
recommendations.
Keywords: Alpha-linolenic acid; arachidonic acid; doco-
sahexaenoic acid; eicosapentaenoic acid; infant nutrition;
linoleic acid; maternal health; maternal nutrition; perinatal
development.
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Introduction
Exceptionally rapid growth and development of the fetus
occurs during pregnancy and for the young child during
the first several years of life. Brain growth accelerates
during the second half of pregnancy and remains high
during the first year of life with continued growth for the
next several years w23x. During this time many develop-
mental milestones are reached in terms of cognitive,
visual, and motor development. It is essential that high
quality nutrition be supplied to the fetus, infant and
young child to ensure that all essential nutrient needs are
met. Breastfeeding should be promoted, protected and
supported, initially as the sole source of nutrition and
continuing upon the timely introduction of complimentary
foods. If exclusive breastfeeding is not possible, the only
appropriate substitute during the first year of life is an
infant formula or a follow-on formula w52, 90x. The lipids
of human milk and formula are of critical importance dur-
ing this time period for several reasons. First of all, they
are a major energy source to support appropriate growth.
Both human milk and infant formula provide about half
of their calories as fat. In addition, infants cannot syn-
thesize omega-3 and omega-6 polyunsaturated fatty
acids (PUFA). These PUFA are required for normal growth
and maturation of numerous organ systems, most impor-
tantly the brain and eye.
In 2001 the Child Health Foundation asked investiga-
tors in the field of LC-PUFA and perinatal development
to review the available scientific data on LC-PUFA in
infancy w52x. At that time, a consensus statement and
recommendations for health-care providers on perinatal
LC-PUFA supply were developed w51x. One of the rec-
ommendations of the 2001 workshop was to update the
consensus statement and recommendations as addition-
al data became available. More recently, a European
Commission (EC) supported consensus group developed
recommendations for dietary fat intakes for pregnant and
lactating women, based on systematic literature reviews
and a consensus conference held with international
experts in the field w53x. The aim of the present publi-
cation is to review the recent literature and current
recommendations regarding LC-PUFA as they pertain to
maternal nutrition during pregnancy and lactation and
term infant nutrition during the first months of life, and to
provide updated recommendations for health-care pro-
viders. Based on analysis of the recent literature, the
authors of this review who are involved in research in the
areas of maternal and infant nutrition unanimously
agreed on the conclusions and recommendations provid-
ed here, which are supported by the World Association
of Perinatal Medicine (www.wapm.info), the Early Nutri-
tion Academy (www.metabolic-programming.org/academy.
htm), and the Child Health Foundation (www.
kindergesundheit.de).
Essential fatty acids
Humans can synthesize saturated and monounsaturated
fatty acids, but they cannot synthesize the n-3 and the
n-6 families of PUFA. The parent fatty acids of these
families, alpha-linolenic acid (18 carbons, three double
bonds with the first double bond in the n-3 position,
C18:3n-3, ALA) and linoleic acid (C18:2n-6, LA) are
essential fatty acids and must be present in the diet. The
fatty acids of these families cannot be interconverted, so
both n-3 and n-6 fatty acids are essential. ALA and LA
are converted to longer chain, more highly unsaturated
fatty acids through enzymatic chain elongation and de-
saturation. ALA is converted to eicosapentaenoic acid
(C20:5n-3), then on to docosahexaenoic acid (C22:6n-3,
DHA), whereas LA is converted to arachidonic acid
(C20:4n-6, AA). DHA is a critical component of cell mem-
branes, especially in the brain and the retina. AA is both
a membrane component and a precursor to potent sig-
naling molecules, the prostaglandins and leukotrienes.
Figure 1 shows the pathway for conversion of ALA to
DHA and LA to AA. The chain elongation/desaturation
enzymes are shared by both n-3 and n-6 fatty acids with
competition between substrates for these enzymes w15,
43x.
Fetal and infant LC-PUFA accumulation
Brain accumulation of DHA starts in utero, with quanti-
tatively marked deposition in the second half of gestation
w20, 68, 69x. DHA accumulation in brain continues after
birth, reaching a total brain DHA deposition of about 4 g
between two and four years of age w68, 69x. DHA is also
an important structural component of retina lipids, com-
prising as much as 50% of total fatty acids of rod and
cone outer segments w82x. Unlike DHA, other n-3 LC-
PUFAs do not accumulate to any appreciable extent in
the growing brain and eye w68x. Brain accumulation of
AA also occurs during pre- and post-natal development.
Elongation and desaturation enzymes for PUFA con-
version are present in the fetal liver early in gestation, but
activity appears to be low before birth w86x. Therefore,
the n-6 and n-3 LC-PUFA that the fetus accumulates in
utero are derived predominantly through placental trans-
fer, with the amounts in cord blood influenced by the
maternal diet w55x. Both preterm and term infants are
capable of synthesizing DHA and AA w18, 22, 74, 76x;
conversion rates of LA to AA and of ALA to DHA are
influenced by genetics, gender, and the amount of pre-
cursor fatty acids available in the diet w39x. Human milk
always contains both AA and DHA, whereas, in the past,
infant formulae had neither. Synthesis rates of these LC-
PUFA from C18 precursors are insufficient to maintain
stable plasma and red blood cell LC-PUFA levels in
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Figure 1 Metabolic conversion of the essential fatty acids linoleic acid (omega-6 series) and alpha-linolenic acid (omega-3 series)
to long-chain polyunsaturated fatty acids (LC-PUFA) (Modified from Koletzko Larque´ and Demmelmair, J Perinat Med. 2007).
infants receiving unsupplemented formula, and LC-PUFA
levels decline in infants fed unsupplemented formula
compared to those fed human milk (for example w4, 33x).
Delivery of LC-PUFA to the fetus and infant
LC-PUFA during pregnancy
Maternal dietary intake of LC-PUFA and lifestyle influ-
ence the LC-PUFA levels available for transfer to the
fetus w4, 27, 35, 55x. The physiological importance of
DHA is supported by its active and preferential maternal-
fetal placental transfer, which is mediated by specific fat-
ty acid transfer proteins (FATP-1 and FATP-4) and
membrane binding proteins that favor placental transport
of DHA over other fatty acids such as LA w54, 59x. Spon-
sored by the European Commission, the Perinatal Lipid
Nutrition Project (PeriLip) and The Early Nutrition Pro-
gramming Project (EARNEST) in collaboration with sev-
eral international scientific societies, recently developed
consensus recommendations concerning dietary fat
intake for pregnant and lactating women, based on a
systematic review of available evidence and a formal
consensus process w53x. The consensus document rec-
ommends an average DHA intake of at least 200 mg/day
during both pregnancy and lactation. Women of child-
bearing age can meet the recommended intake of DHA
by consuming one to two portions of sea fish per week,
including fatty fish, which is a good source of n-3 LC-
PUFA. Consumption of this amount of fish does not gen-
erally exceed the tolerable intake levels of environmental
contaminants. Other sources of n-3 LC-PUFA include
enriched foods and dietary supplements. Dietary ALA,
the precursor to DHA, is much less effective in promoting
optimal DHA status than consumption of preformed DHA
and is insufficient to promote desirable levels of DHA
deposition in the fetal brain w14, 34x.
A number of studies have demonstrated that intake of
fish, fish oils or single cell n-3 LC-PUFA oils during preg-
nancy result in slightly longer gestation, marginally higher
birth weight, and reduced risk of preterm delivery w42, 53,
65, 83x. Multiple pregnancies and closely spaced preg-
nancies create an even higher demand for maternal LC-
PUFA w71, 92x. A multinational epidemiological study
indicated that higher concentrations of DHA in maternal
milk and greater seafood consumption predict a lower
prevalence of postpartum depression (PPD). The highest
prevalence was found in South Africa (24.5%) and the
lowest in Japan (2%) w37x.
LC-PUFA in lactation
Human milk provides LA, ALA, DHA, AA, and other LC-
PUFA to breastfed infants. The level of AA is relatively
constant on a worldwide basis whereas the level of DHA
is more variable and depends on maternal diet and life-
style w1, 3, 67, 81, 91x. Population means of AA in human
milk range between 0.35–0.7 weight % of total fatty
acids w67, 81, 91x, whereas means of DHA range from
0.17% to 1.0% of total fatty acids w91x. Lactating women
supplemented with DHA have an increase in milk DHA
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levels w28, 48x. Gibson et al. w32x reported that a dose-
dependent relationship exists between maternal DHA
consumption and DHA levels in human milk. In this study
human milk DHA levels above 0.8% of total fatty acids
did little to increase the plasma or RBC DHA content of
the study infants.
LC-PUFA in infant formulae
Infants have been fed formulae with various concentra-
tions and ratios of C18 PUFA, ALA and LA, in attempts
to match the LC-PUFA status of breastfed infants (as
measured by plasma or RBC LC-PUFA levels). Although
DHA levels are marginally higher in infants fed formulae
with a high ALA/LA ratio compared to groups fed lower
ratios, they do not reach those found in breastfed infants,
whereas AA levels are suppressed at high ALA/LA ratios
w19, 47, 63x. Numerous studies have compared the LC-
PUFA levels in plasma and RBC of infants fed human
milk, formulae supplemented with LC-PUFA or unsupple-
mented formula w8, 33x. Circulating levels of both DHA
and AA in breastfed infants can only be matched with the
addition of both of these fatty acids to formula. Provision
of n-3 LC-PUFA without AA in infant formula may reduce
circulating AA in preterm infants w39, 50, 57x and in term
infants w56x and may thus negatively affect growth in
these infants w16, 58, 73x.
Infant outcomes
Dietary LC-PUFA during infancy and visual
development
Infants are born with a poorly developed visual system,
but during the first year of life vision develops rapidly w75,
87x. Measures of visual development typically involve
either electrophysiological measures (visual evoked
potential, VEP) or forced choice preferential looking
(FPL). Methodological differences are important since
electrophysiological evaluations are more sensitive than
FPL, and therefore, are capable of detecting smaller dif-
ferences between groups w84x.
Numerous studies have evaluated the effect of DHA
status on the developing visual system. Malcolm et al.
w66x provided fish oil during pregnancy and found that
the DHA status of the infants at birth was related to the
maturity of visual evoked potential at 2.5 and six months
of age. Eye-hand coordination at the age of 2.5 years is
improved in infants whose mothers received high dose
fish oil during pregnancy w24x. Observational studies
found that human milk DHA levels were positively cor-
related to visual development in breast-fed infants w44,
49x. Studies which evaluated lactating women receiving
either an n-3 LC-PUFA supplement or placebo did not
find a difference between groups w33, 48, 61x, although
several studies identified a significant positive correlation
between visual acuity and milk DHA levels or infant DHA
status w33, 61x. Other studies have evaluated the effect
of infant formula LC-PUFA supplementation on visual
development with infants receiving supplemented infant
formula from shortly after birth for various amounts of
time. Some studies report positive results, whereas
others find no statistically significant difference between
formula groups (reviewed in w30, 75, 79x). A number of
the studies reporting no positive LC-PUFA effects were
conducted with very low DHA levels.
Two studies have evaluated the role of the provision of
LC-PUFA during the second six months of life with for-
mula or complementary foods on visual development,
and these studies found improved vision when infants
received LC-PUFA during this time compared to controls
w40, 41x.
Three studies have examined the potential long term
benefits of LC-PUFA supplemented formulae. One study
did not find an improvement in stereo-acuity at 4–6 years
of age when infants received an LC-PUFA fortified for-
mula w80x. A second study found no differences between
breastfed infants, or infants receiving either LC-PUFA for-
tified formula or control formula at 39 months of age w5x.
In a third study infants received various formulae (control
formula, formula containing DHA alone, formula contain-
ing AA and DHA), or were breastfed for 17 weeks and
were assessed at four years of age for vision and IQ.
Both vision and IQ were significantly poorer in the control
group compared to breastfed infants, whereas no such
differences were found when the fortified formula groups
were compared to the breastfed group w9x.
A Cochrane review w79x did not find a significant rela-
tionship between DHA supplementation and vision or
general development in infants; however, the author not-
ed that a benefit of increased dietary LC-PUFA on infor-
mation processing was possible. One problem with the
evaluation of the published studies is the wide range of
LC-PUFA levels evaluated (from 0.1 weight % DHA to
0.36% DHA). Two groups w60, 87x have developed mod-
els in which infant DHA status is related to dietary ALA
(and assumed subsequent conversion to DHA) and die-
tary DHA. These models demonstrated a positive corre-
lation between visual development and dietary n-3 fatty
acid intake.
Dietary LC-PUFA during infancy and cognitive
development
Given that the predominant n-3 and n-6 fatty acids in
brain are DHA and AA, it is reasonable to consider the
effects of maternal supplementation with DHA during
pregnancy and lactation or LC-PUFA in infant formula on
cognitive development. Studies have employed a variety
of tests, such as a test of general developmental (e.g.,
the Bayley Scales of Infant Development) and psycho-
motor development (Brunet-Lezine test), and more spe-
cific evaluations, such as problem solving and language
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development tests. Each of these measures assesses
different components of brain development; therefore
inconsistent results might not be surprising w17, 70, 88x.
Epidemiological evidence reports an association
between higher levels of maternal fish consumption dur-
ing pregnancy and developmental outcomes. Higher
maternal fish consumption during pregnancy resulted in
short term benefits for infants (higher novelty preference
on visual recognition memory w72x, and longer term ben-
efits (higher scores of verbal intelligence quotient and
other behavioral outcome measures in the children up to
an age of eight years w38x. In breastfed infants, DHA stat-
us at two months of age correlated with language pro-
duction and comprehension at 14 and 18 months of age
w44, 45x. Jensen et al. w48x evaluated measures of cog-
nitive development among infants of lactating women
supplemented for four months after delivery with either
DHA (200 mg/day) or control vegetable oil and assessed
development. At 30 months of age, a significant increase
in Bayley Psychomotor Development Index was found,
although no differences were found in vision or the Bay-
ley Mental Development Index during the study.
In a double blind randomized trial, maternal supple-
mentation during pregnancy and lactation with cod liver
oil providing about 1.2 g DHA and 0.8 g EPA led to a 4%
point advantage in children’s scores on the Kaufmann
ABC test (a standardized intelligence test) in the sub-
group of children tested at the age of four years w36x.
Two other studies during lactation have not demonstrat-
ed significant improvements in cognitive development
w28, 48x and one study reported a transient decrease in
vocabulary comprehension at one year of age, but not at
two years w62x. However, controlling all the variables in
evaluations of breast-feeding and cognitive development
is difficult.
Mixed results have been found in infant formula stud-
ies. Some studies have demonstrated significant benefits
in cognitive development when infants have received LC-
PUFA containing formulae, while other studies have not
w30, 70, 75x. As noted above, a Cochrane review w79x
found that information processing may be improved by
dietary LC-PUFAs. As with studies measuring visual
response, studies employing -0.2% DHA generally did
not report positive effects.
Motor development may be influenced by early LC-
PUFA supply. Spontaneous motor behavior of infants,
reported as a set of parameters termed general move-
ments, measures nervous system organization early in
life. Following two months of formula feeding with or
without LC-PUFA, or breastfeeding, the infants who had
been randomized to be fed unsupplemented formula had
a higher proportion of abnormal spontaneous general
movements w10x. At 18 months of age the groups did not
differ in either Bayley Scales of Infant Development or
Hempel scores, a standardized assessment technique for
the detection of minor signs of neurological dysfunction
w11x. Maternal fatty acid status (measured by umbilical
cord blood fatty acid analysis) and neurological devel-
opment was also assessed by Bouwstra and colleagues.
At three months of age infants born to mothers with low
AA status had significantly higher levels of abnormal gen-
eral movement scores w12x and low DHA status at birth
was associated with lower Hempel scores at 18 months
w13x. In a randomized trial the intake of high dosages of
fish oil providing 2.2 g DHA and 1.1 g EPA per day to
women during the second half or pregnancy led to
improved eye-hand coordination of the children at the
age of 2.5 years w26x. Thus, both perinatal status and
post-natal supply of LC-PUFA may contribute to infant
development.
Other effects of LC-PUFA
Dietary supplementation of infant formula with DHA and
AA has been associated with lower blood pressure at the
age of six years w31x. Compared with children given
unsupplemented infant formula during the first four
months of life, those fed formula with DHA and AA had
significantly lower mean blood pressure (mean differ-
ence: y3.0 mm Hg) and diastolic blood pressure (mean
difference: y3.6 mm Hg) at six years of age. Since blood
pressure tends to track from childhood into adult life, ear-
ly exposure to dietary LC-PUFA might have lasting
effects on reduced blood pressure and cardiovascular
risk.
There are also indications that early LC-PUFA provision
may modulate immune response. Infants born to atopic
pregnant women who were randomized to receive a high
dosage marine oil supplement during the second half of
pregnancy demonstrated an improved response to anti-
gen skin prick test at age one year and less severe atopic
dermatitis compared to infants whose mothers received
placebo w25x. A study in preterm infants demonstrated
that lymphocyte populations, cytokine production and
antigen maturity were similar between infants receiving
human milk and an LC-PUFA supplemented formula,
whereas infants receiving an unsupplemented formula
differed in all these parameters w29x.
One study has demonstrated that maternal and cord
blood LC-PUFA status is predictive of bone mass in
healthy term infants w89x.
Means of increasing LC-PUFA intake for
mothers and infants
Numerous studies have evaluated the effects and safety
of LC-PUFA supply to pregnant and lactating women
w43x. These studies have taken into account the use of
DHA alone or fish oils with various levels of DHA and
EPA. Fish consumption may increase the exposure of the
mother and fetus to contaminants such as methylmer-
cury, dioxins and polychlorinated biphenyls (PCB) and
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Table 1 Conclusions and recommendations on Dietary fat intakes for pregnant and lactating women of the EU supported the
Perinatal Lipid Intake Working Group (from Koletzko et al. w53x).
1. Dietary fat intake during pregnancy and lactation, as a proportion of energy intake, should be the same as that recommended
for the general population
2. The omega-3 long-chain polyunsaturated fatty acid (n-3 LC-PUFA), docosahexaenoic acid (DHA), must be deposited in
adequate amounts in brain and other tissues during fetal and early postnatal life. Several studies have shown an association
between maternal dietary intake of fatty fish, or oils providing n-3 LC-PUFA during pregnancy and/or lactation and visual and
cognitive development as well as other functional outcomes of the infants. Pregnant and lactating women should aim to
achieve a dietary intake of n-3 LC-PUFA that supplies a DHA intake of at least 200 mg/day. Intakes of up to 1 g/day of DHA
or 2.7 g/day of n-3 LC-PUFA have been used in randomized trials without occurrence of significant adverse effects
3. Women of childbearing age can meet the recommended intake of DHA by consuming one to two portions of sea fish per
week, including fatty fish, which is a good source of n-3 LC-PUFA. This intake of fatty fish rarely exceeds the tolerable intake
of environmental contaminants. Dietary fish should be selected from a wide range of species without undue preference for
large predatory fish, which are more likely to be contaminated with methylmercury
4. Intake of the precursor, alpha-linolenic acid, is far less effective with respect to DHA deposition in fetal brain than the intake of
preformed DHA
5. There is no evidence that women of childbearing age whose dietary intake of linoleic acid is adequate need an additional
dietary intake of arachidonic acid
6. Some studies have shown that maternal intake of fish, fish oils or n-3 LC-PUFA results in a slightly longer duration of
gestation, a somewhat higher birth weight and a reduced risk of early preterm delivery. The clinical importance of such
effects with respect to infant health has not been fully elucidated
7. Screening for dietary inadequacies should be performed during pregnancy, preferably during the first trimester. If less than
desirable dietary habits are detected, individual counselling should be offered during pregnancy as well as during lactation
also increase the levels of these contaminants in breast
milk. The European Food Safety Authority has evaluated
this subject and concluded that women of childbearing
age consuming two fish meals per week (the recom-
mended level during pregnancy and lactation) should
generally not exceed the provisional tolerable weekly
intake of environmental pollutants. The recent cohort
studies reporting a positive relationship between higher
sea fish consumption by pregnant women and improved
child cognition, verbal intelligence quotient, fine motor
coordination and prosocial behavior w38, 72x support the
conclusion that the beneficial effects of higher n-3 LC-
PUFA supply from sea fish on child development out-
weigh the potential disadvantages from increased
intakes of contaminants w53x.
Sources of LC-PUFA during the first year of life include
human milk, infant or follow-on formula enriched with LC-
PUFA and complementary foods such as egg, fatty fish,
and meat. Safety is of primary importance. Highly refined
oils from single cell organisms (specific algal and fungal
organisms), eggs, or fish as sources of DHA and/or AA
are appropriate for use in infant formulae and weaning
foods if the purity and safety of the specific oil used has
been documented. A systematic review of effects of LC-
PUFA supplementation of infant formulae on infant
weight gain, based on original data analysis, indicates
that the addition of both DHA and AA to infant formula
supports growth comparable to that seen in infants fed
unsupplemented formula w64x. A limited number of stud-
ies with infant formula supplemented with DHA alone
also seemed to produce acceptable weight gain in term
infants w64x, but the available data seem too limited to
draw final conclusions.
If LC-PUFAs are added to formulae, the combined
addition of DHA and AA appears appropriate. The relative
constancy of AA supply to the infant through breastfeed-
ing w91x clearly demonstrates that breastfed infants will
receive both AA and DHA. LC-PUFAs are the precursors
to eicosanoids, highly bioactive oxygenated derivatives
of their parent LC-PUFAs. AA is the predominant pre-
cursor fatty acid, due to its high concentration in
membrane phospholipids. AA can be oxygenated by
three different enzymatic systems: cyclooxygenases
(forming prostaglandins and thromboxane), lipoxyge-
nases (forming leukotrienes) and cytochrome P450
monooxygenases (forming 19- and 20 HETE). The bio-
logical activities of the eicosanoids are extensive. For
example, one prostaglandin, PGE2, affects the vascula-
ture, airways, stomach, kidney, neutrophils, lymphocytes,
and pain perception. Sellmayer and Koletzko w78x have
reviewed the roles of eicosanoids in infants. A large data-
base exists concerning not only the safety, but also the
efficacy, of infant formula containing both AA and DHA.
These facts, together, support the addition of both AA
and DHA when LC-PFUAs are added to formula.
Brain development continues during early childhood,
indicating the continued need for adequate intakes of
DHA and AA. With the introduction of complementary
foods, infants consume less breast milk or formula, and
the total dietary intake of LC-PUFA may decrease unless
the introduced foods contain LC-PUFA. Regular intakes
of egg yolk, fish, liver or other LC-PUFA fortified foods
may be advisable w46x, but the exact requirements for
LC-PUFA for older infants and toddlers are not known.
Since the dietary supply of LC-PUFA might be beneficial
for continued optimal neurological function in childhood
Koletzko et al., The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy 11
Article in press - uncorrected proof
Table 2 Recommended LC-PUFA supply with infant formula
and baby foods.
1. The available evidence strongly supports benefits of
adding DHA and AA to infant formula.
2. DHA should reach at least 0.2% of fatty acids and not
exceed 0.5% of fatty acids.
3. Levels of added AA should at be least equal to those of
added DHA.
4. The amount of EPA added should not exceed the amount
of added DHA.
5. It appears advisable to continue the provision of dietary
sources of LC-PUFA during the second six months of life,
but optimal amounts cannot be specified at this time
w2, 6, 7x, the use of infant/toddler foods providing DHA
and AA should be further evaluated.
Recommendations for LC-PUFA for pregnant
and lactating women
Recent European Commission supported consensus
recommendations based on systematic literature reviews
and an expert consensus process include the advice that
pregnant and lactating women should aim at achieving
an average DHA intake of at least 200 mg per day (Tables
1 and 2).
Recommendations for LC-PUFA for infants
In agreement with other reports, the authors of this
review strongly endorse breastfeeding as the preferred
method of feeding healthy infants. They also emphasize,
however, the importance of the provision of a balanced
dietary intake for breastfeeding women, and this should
include a regular supply of DHA. This review considered
the present guidelines from an ESPGHAN coordinated
International Expert Group providing recommendations
on the composition of infant formula, the Codex Alimen-
tarius proposal for a global infant formula standard, and
the EU Commission Directive on infant formula and fol-
low-on formula w21, 52, 85x. The authors of this review
conclude that the available evidence supports the addi-
tion of DHA to infant formula. The addition of at least
0.2% of fatty acids as DHA appears necessary for
achieving a benefit on functional endpoints, but DHA lev-
els should not exceed 0.5% of fatty acids because sys-
tematic evaluation of higher levels of intake have not
been published (Table 2). Based on current knowledge,
infant formula contents of AA should be at least those of
added DHA, and EPA should not exceed levels of DHA.
Dietary LC-PUFA supply should continue during the sec-
ond six months of life, but there is currently not sufficient
information for quantitative recommendations for addi-
tion of LC-PUFA to follow-on formula or complementary
foods.
Recommendations for future LC-PUFA
research
• Future research should consider short- and long-term
effects of LC-PUFA status prior to and during preg-
nancy, lactation, and infancy according to inter-indi-
vidual differences, such as genetic variation in fatty
acid desaturase activities or gender.
• Studies addressing subgroups with potential specific
needs and benefits, such as women with at risk preg-
nancies, restricted dietary intakes, or short time inter-
vals between pregnancies are encouraged.
• Supplementation studies should aim to examine
growth, body composition and bone mineralization,
visual and cognitive development, as well as effects
on immune outcomes (such as allergy and inflamma-
tory disorders), and cardiovascular function.
• Studies evaluating different amounts of LC-PUFA, and
the specific effects of AA supply, with sufficient dura-
tion of intake, adequate sample sizes, and standard-
ized methodology for outcome measurements need
careful consideration.
• Infant formula studies should consider various levels
of DHA in order to determine possible dose-response
relationships and to elucidate potential immediate and
long-term benefits.
• Dose-response studies of LC-PUFA intake during the
second six months of life should be undertaken.
• Simplified measures of dietary supply and of LC-PUFA
status should be developed and evaluated.
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